Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference ca
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
02:59pm, Friday, 29'th Mar 2024
Two patients were treated with KYV-101, a fully human anti-CD19 CAR T-cell product candidate, in Germany as part of a named patient program after failure to respond to conventional therapies The treat
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
04:05pm, Tuesday, 26'th Mar 2024
Advanced clinical development in two broad areas of autoimmune disease: rheumatology and neurology Strong balance sheet, bolstered by recent public offering, expected to fund operations into 2026 EMER
The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants The clinical study wi
Everyone's Talking About These 2 Biotech IPO Stocks, But Are They Buys?
08:17am, Sunday, 25'th Feb 2024
Biotech businesses tend to be volatile after their initial public offerings. Kyverna Therapeutics raised more than twice what was initially expected.
EMERYVILLE, Calif. , Feb. 12, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients s
U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A Six IPO Week
04:27am, Saturday, 10'th Feb 2024
U.S. IPO Weekly Recap: Autoimmune Biotech Kyverna Therapeutics Gains 37% In A Six IPO Week
Gilead-backed Kyverna Therapeutics valued at $1.4 bln in stellar debut
01:43pm, Thursday, 08'th Feb 2024
Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion.
Kyverna Therapeutics to raise $319 million in upsized IPO
11:05pm, Wednesday, 07'th Feb 2024
Gilead-backed Kyverna Therapeutics on Wednesday said it will raise $319 million at a valuation of $898.1 million in an upsized U.S. initial public offering (IPO).
Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering
10:29pm, Wednesday, 07'th Feb 2024
EMERYVILLE, Calif. , Feb. 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients su
Gilead-backed Kyverna Therapeutics aims for $857.3 mln valuation in upsized IPO
06:58am, Tuesday, 06'th Feb 2024
Kyverna Therapeutics expects up to $857.3 million valuation in its U.S. initial public offering (IPO), the biotechnology company said on Tuesday as it raised its offering.
U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings
06:16am, Sunday, 04'th Feb 2024
Sports equipment and apparel maker Amer Sports priced below the range to raise $1.3 billion at a $6.4 billion market cap. CNS disorder biotech Alto Neuroscience priced its upsized IPO at the top of th
Kyverna Therapeutics targets up to $711 mln valuation in US IPO
07:09am, Thursday, 01'st Feb 2024
Biotechnology company Kyverna Therapeutics said on Thursday it was aiming for a market valuation of up to $711 million in its U.S. initial public offering (IPO).
Kymera Therapeutics Begins U.S. IPO Effort (Private:KYTX)
08:38pm, Wednesday, 05'th Aug 2020
Kymera Therapeutics has filed to raise $100 million in an IPO, although the final figure may vary. The firm is advancing drug treatment candidates for skin conditions and cancers.
